Kintor Pharma is a company that makes medicine for sick people. They tried to make a medicine for hair loss, but it didn't work very well. So, they decided to make it a product you can buy without a doctor's prescription, like shampoo. They hope this will help them make money and be more successful. Read from source...

- The article's title is misleading and sensationalized, implying that Kintor Pharma is a major player or a success story in the cosmetic industry, when in reality, it is a biotech company that failed to develop a successful drug and is now resorting to a less regulated route for its product.
- The article's introduction sets a negative tone by mentioning the company's massive loss of market value and the lack of revenue generation, which is not relevant to the topic of the article, which is the company's decision to launch an over-the-counter hair-loss product.
- The article mentions Kintor's earlier failed clinical trial for KX-826, but does not explain why the company still decided to pursue the product as a cosmetic ingredient, nor does it provide any evidence or analysis of the potential benefits or drawbacks of this decision.
- The article compares Kintor Pharma to other companies in the cosmetic industry, such as Yonghe Medical and Cutia Therapeutics, but does not provide any meaningful comparisons or insights, such as their market share, revenue, or growth potential, which would be more relevant for readers.
- The article concludes with a vague statement about the company's interim report, which is unlikely to show much progress, and the investors' expectations, without providing any concrete data or projections.

### AI:
AI's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:

- The article's title is misleading and sensationalized, implying that Kintor Pharma is a major player or a success story in the cosmetic industry, when in reality, it is a biotech company that failed to develop a successful drug and is now resorting to a less regulated route for its product.
- The article's introduction sets a negative tone by mentioning the company's massive loss of market value and the lack of revenue generation, which is not relevant to the topic of the article, which is the company's decision to launch an over-the-counter hair-loss product.
- The article mentions Kintor's earlier failed clinical trial for KX-826, but does not explain why the company still decided to pursue the product as a cosmetic ingredient, nor does it provide any evidence or analysis of the potential benefits or drawbacks of this decision.
- The article compares Kintor Pharma to other companies in the cosmetic industry, such as Yonghe Medical and Cutia Therapeutics, but does not provide any meaningful comparisons or insights, such

Step 1: Analyze the tone of the article and the author's opinion
Step 2: Look for keywords and phrases that indicate sentiment
Step 3: Determine the overall sentiment based on the majority of indicators

### Final answer: Neutral